Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network

被引:233
|
作者
Tiemann, M
Schrader, C
Klapper, W
Dreyling, MH
Campo, E
Norton, A
Berger, F
Kluin, P
Ott, G
Pileri, S
Pedrinis, E
Feller, AC
Merz, H
Janssen, D
Hansmann, ML
van Krieken, H
Möller, P
Stein, H
Unterhalt, M
Hiddemann, W
Parwaresch, R
机构
[1] Univ Hosp Schleswig Holstein, Dept Haematol, D-24116 Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Dept Haematopathol, D-24116 Kiel, Germany
[3] Univ Hosp Schleswig Holstein, Lymph Node Registry, D-24116 Kiel, Germany
[4] Univ Munich, Div Med 3, Munich, Germany
[5] Dept Haematopathol, Barcelona, Spain
[6] Barts & London NHS Trust, Dept Histopathol, London, England
[7] Ctr Hosp Lyon Sud, Dept Pathol, F-69310 Pierre Benite, France
[8] Leiden Univ, Dept Pathol, Leiden, Netherlands
[9] Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany
[10] Univ Bologna, Bologna, Italy
[11] Dept Pathol, Locarno, Switzerland
[12] Univ Hosp Schleswig Holstein, Dept Pathol, Lubeck, Germany
[13] Goethe Univ Frankfurt, Dept Pathol, D-6000 Frankfurt, Germany
[14] Univ Nijmegen, Dept Pathol, Nijmegen, Netherlands
[15] Univ Ulm, Dept Pathol, Ulm, Germany
[16] Univ Berlin, Dept Pathol, Berlin, Germany
关键词
mantle cell lymphoma; cytology; growth pattern; Ki-67; index; mitotic index;
D O I
10.1111/j.1365-2141.2005.05716.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mantle cell lymphoma (MCL) is a distinct lymphoma subtype with a particularly poor clinical outcome. The clinical relevance of the morphological characteristics of these tumours remains uncertain. The European MCL Network reviewed 304 cases of MCL to determine the prognostic significance of histopathological characteristics. Cytomorphological subtypes, growth pattern and markers of proliferation (mitotic and Ki-67 indices) were analysed. In addition to the known cytological subtypes, classical (87.5%), small cell (3.6%), pleomorphic (5.9%) and blastic (2.6%), we identified new pleomorphic subgroups with mixtures of cells (classical + pleomorphic type; 1.6%) or transitions (classical/pleomorphic type; 1.6%), which, however, did not differ significantly in overall survival time. Exactly 80.5% of cases displayed a diffuse growth pattern, whereas 19.5% of cases had a nodular growth pattern, which was associated with a slightly more favourable prognosis. A high proliferation rate (mitotic or Ki-67 indices) was associated with shorter overall survival. Cut-off levels were defined that allowed three subgroups with different proliferation rates to be discriminated, which showed significantly different clinical outcomes (P < 0.0001). Based on this large clinicopathological study of prospective clinical trials, multivariate analysis confirmed the central prognostic role of cell proliferation and its superiority to all other histomorphological and clinical criteria.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 50 条
  • [41] Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma - Results from Randomized Trials of the European MCL Network
    Hoster, Eva
    Rosenwald, Andreas
    Berger, Francoise
    Bernd, Heinz-Wolfram
    Hartmann, Sylvia
    Loddenkemper, Christoph
    Barth, Thomas
    Brousse, Nicole
    Pileri, Stefano
    Rymkiewicz, Grzegorz
    Kodet, Roman
    Unterhalt, Michael
    Kluin-Nelemans, Johanna C.
    Hermine, Olivier
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    Klapper, Wolfram
    BLOOD, 2014, 124 (21)
  • [42] Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study.
    Goy, A.
    Bernstein, S. H.
    Kahl, B. S.
    Djulbegovic, B.
    Robertson, M. J.
    Boral, A.
    Shi, H.
    Fisher, R. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 425S - 425S
  • [43] Increased Charlson Comorbidity Index (CCI) Is Not Associated with Inferior Clinical Outcomes in Patients with Mantle Cell Lymphoma (MCL)
    Ridley, Derrick
    Goyal, Subir
    Calzada, Oscar
    Churnetski, Michael C.
    Koff, Jean L.
    Lechowicz, Mary Jo
    Flowers, Christopher R.
    Cohen, Jonathon B.
    BLOOD, 2018, 132
  • [44] Clinical Characteristics and Outcomes of Primary Versus Secondary Gastrointestinal (GI) Mantle Cell Lymphoma (MCL)
    Wang, Yucai
    Tun, Aung
    Castellino, Alessia
    Inwards, David
    Witzig, Thomas
    Habermann, Thomas
    Nowakowski, Grzegorz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S257 - S258
  • [45] Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL network
    Klapper W.
    Hoster E.
    Determann O.
    Oschlies I.
    van der Laak J.
    Berger F.
    Bernd H.W.
    Cabeçadas J.
    Campo E.
    Cogliatti S.
    Leo Hansmann M.
    Kluin P.M.
    Kodet R.
    Krivolapov Y.A.
    Loddenkemper C.
    Stein H.
    Möller P.
    Barth T.E.F.
    Müller-Hermelink K.
    Rosenwald A.
    Ott G.
    Pileri S.
    Ralfkiaer E.
    Rymkiewicz G.
    van Krieken J.H.
    Wacker H.H.
    Unterhalt M.
    Hiddemann W.
    Dreyling M.
    Journal of Hematopathology, 2009, 2 (2) : 103 - 111
  • [46] Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network
    Drandi, Daniela
    Alcantara, Marion
    Benmaad, Ichrafe
    Soehlbrandt, Arian
    Lhermitte, Ludovic
    Zaccaria, GianMaria
    Ferrante, Martina
    Genuardi, Elisa
    Mantoan, Barbara
    Villarese, Patrick
    Cheminant, Morgane
    della Starza, Irene
    Ciabatti, Elena
    Bomben, Riccardo
    Jimenez, Cristina
    Callanan, Mary
    Abdo, Chrystelle
    Eckert, Cornelia
    Ribrag, Vincent
    Cortelazzo, Sergio
    Dreyling, Martin
    Hermine, Olivier
    Delfau-Larue, Marie-Helene
    Pott, Christiane
    Ladetto, Marco
    Ferrero, Simone
    Macintyre, Elizabeth
    HEMASPHERE, 2020, 4 (02):
  • [47] Allogeneic transplantation for poor risk mantle cell lymphoma (MCL): Chemosensitivity predicts superior outcome.
    Khouri, IF
    Saliba, RM
    Younes, A
    Acholonu, S
    Andersson, B
    Bibawi, S
    de Lima, M
    Fayad, L
    Giralt, S
    Hagemeister, FB
    Korbling, M
    Rodriguez, MA
    Romaguera, J
    Cabanillas, F
    Champlin, RE
    BLOOD, 2001, 98 (11) : 416A - 416A
  • [48] Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh, Amer
    Kaufman, Adrienne
    Wang, Yucai
    Jain, Preetesh
    Srour, Samer A.
    Wang, Michael
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (11) : 1614 - 1625
  • [49] Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Amer Beitinjaneh
    Adrienne Kaufman
    Yucai Wang
    Preetesh Jain
    Samer A Srour
    Michael Wang
    Current Treatment Options in Oncology, 2022, 23 : 1614 - 1625
  • [50] Initial observation without therapy in patients with asymptomatic, newly diagnosed mantle cell lymphoma (MCL)
    Martin, P.
    Chadburn, A.
    Christos, P.
    Furman, R.
    Ruan, J.
    Elstrom, R.
    Niesvizky, R.
    Ely, S.
    Chen-Kiang, S.
    Coleman, M.
    Leonard, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 85 - 85